Biomedical Engineering Reference
In-Depth Information
Table 10.2
Published Clinical Studies on ALA- and MAL-PDT for Bowen's Disease
Light Source
(Wavelength
in nm)
Incubation
Period (hr)
# Lesions Treated
(# Patients)
Reference
ALA Preparation
Location of BD
Response Rate
Follow-up (mo)
Morton (116) (1996)
20% Emulsion vs.
cryotherapy;
repeated after
2 mo if required
4
40 (20 lesions were
treated with
ALA-PDT)
Desktop lamp
300 W xenon
short arc
(125 J/cm
2
at a
fl uence rate of
70 mW/cm
2
)
15/20 Lesions
cleared after
1 ALA-PDT
session, the
remaining 5 after
the 2nd session ;
10/20 lesions
cleared after
1 session of
cryotherapy
12
Morton (118) (2000)
20% Emulsion
using red vs.
green light
Legs
4
61 (32 with
red light) in
16 patients
Red (630 ± 15 nm,
125 J/cm
2
) or
green (540 ±
15 nm,
62.5 J/cm
2
) light
88% CR red light ;
48% green light
12
Morton (123) (2001)
20% Emulsion
Face, trunk, and
limbs
4-6
40 Large lesions
greater than
20 mm in
diameter
Filtered red light
(Xenon source,
630 ± 15 nm,
125 J/cm
2
)
78%
12
Leman (122) (2002)
20% Emulsion
Unspecifi ed
4
107 (68)
Filtered red light
(Xenon source,
630 ± 15 nm,
100-125 J/cm
2
)
83%
64 (range
34-84 mo)
Salim (117) (2003)
20% Emulsion vs.
5-FU for 4 wk,
repeated after
6 wk if required
Legs
4
66 Lesions
(33 treated with
ALA-PDT) in
40 patients
Red light (630
+/− 15 nm,
100 J cm
2
)
ALA-PDT 88% CR
vs. 5-FU 67% CR
12
(
Continued
)
